Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mulberry leaf water extract is an aqueous extract of the leaves of the Morus alba plant, standardized in some commercial preparations (such as Reducose) for specific bioactive components like 1-deoxynojirimycin (DNJ)[3]. It is used for its reported hypoglycemic, antioxidant, anti-obesity, and lipid-lowering effects, with actions that include inhibition of carbohydrate digestion enzymes (notably alpha-glucosidase), modulation of mitochondrial function through the AMPK pathway, and increased reactive oxygen species scavenging[1][3][4]. These mechanisms underlie its investigation as a functional food ingredient, dietary supplement, or adjunctive therapy for type 2 diabetes mellitus, metabolic syndrome, obesity, and related disorders. The primary active constituents identified include polysaccharides, alkaloids (such as DNJ), flavonoids, and phenolic acids[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mulberry leaf water extract.